Try our Advanced Search for more refined results

In Re: Actos (Pioglitazone) Products Liability Litigation

  1. September 14, 2015

    Takeda Says Most Actos Claimants Want In On $2.4B Deal

    Takeda Pharmaceutical Company Ltd. said Friday that more than 96 percent of claimants have sought a share of the Japanese drugmaker's proposed deal of up to $2.4 billion to resolve claims that it hid the alleged bladder cancer risks of its diabetes drug Actos. 

  2. April 28, 2015

    Takeda Will Pay Up To $2.4B To Resolve Actos Suits

    Takeda Pharmaceutical Co. Ltd. has agreed to pay up to $2.4 billion to resolve the "vast majority" of product liability suits over its diabetes drug Actos, which plaintiffs have claimed can increase the risks of developing bladder cancer, the Japanese drugmaker confirmed Tuesday.

  3. April 02, 2015

    Takeda Calls $2.2B Actos Settlement Report 'Rumor'

    Takeda Pharmaceutical Co. on Thursday appeared to dismiss as "marketplace rumors" news reports claiming the drugmaker plans to pay $2.2 billion to settle thousands of federal and state suits over the alleged cancer risks of its diabetes drug Actos.

  4. February 09, 2015

    Top Product Verdicts Of 2014 — And The Firms That Won Them

    Last year's biggest product liability verdicts included multibillion-dollar decisions with large punitive damages components — a $6 billion award against Takeda Pharmaceutical Co. Ltd. that was later reduced, and a $23 billion Engle verdict against R.J. Reynolds Tobacco Co. — but with appeals still pending, the eye-popping awards face dramatic cuts.

  5. November 21, 2014

    Eli Lilly, Takeda Win Dismissal Of Ark. Taxpayer Actos Suit

    A Louisiana federal judge on Thursday threw out a proposed class action alleging that Takeda Pharmaceutical Co. and Eli Lilly & Co. ripped off taxpayers by hiding the risks of their diabetes drug Actos, after the Arkansas Supreme Court ruled the drug was properly prescribed by doctors.

  6. October 30, 2014

    Eli Lilly, Takeda Plan Appeal Of $37M Actos Ruling

    Takeda Pharmaceuticals International Inc. and Eli Lilly & Co. said Thursday they will appeal a $37 million punitive damages ruling against them in a suit that alleged the company hid the cancer risks of diabetes drug Actos to keep sales high.

  7. October 28, 2014

    Actos Ruling Sets Up Appellate Clash Over Punitives Ceiling

    A Louisiana federal judge's ruling slashing a $9 billion Actos bladder cancer award to $37 million highlights an ambiguity on upper limits for punitive damages that attorneys say will spur the Fifth Circuit — and maybe even the U.S. Supreme Court — to address the issue more directly.

  8. October 27, 2014

    $9B Takeda, Eli Lilly Actos Damages Slashed To $37M

    A Louisiana federal judge on Monday slashed a $9 billion punitive damages award against Takeda Pharmaceutical Co. Ltd. and Eli Lilly & Co. over the diabetes drug Actos to $36.8 million, ruling the jury "should bow" to the Constitution's due process clause.

  9. August 28, 2014

    Takeda, Eli Lilly Stuck With $9B Actos Verdict

    A Louisiana federal judge on Thursday denied a Takeda Pharmaceutical Co. Ltd. and Eli Lilly & Co. bid to overturn the $9 billion verdict in a bellwether trial over allegations the companies hid the cancer risks of diabetes drug Actos, upholding the jury's punitive damages award.

  10. June 27, 2014

    Takeda, Lilly Say Prejudice Infected $9B Actos Verdict

    Takeda Pharmaceutical Co. Ltd. and Eli Lilly & Co. argued Friday that the sheer size of the $9 billion punitive damages award they suffered in the bellwether personal injury trial over the diabetes drug Actos demonstrates the jury was inflamed by "passion and prejudice," saying its verdict should be overturned.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!